Medtronic Acquires Aptus Endosystems for $110 Million

June 19, 2015—Medtronic plc announced it has acquired the assets of Aptus Endosystems, Inc., a Sunnyvale, California-based, privately held medical device company focused on developing advanced technology for endovascular aneurysm repair (EVAR) and thoracic endovascular aneurysm repair (TEVAR). Medtronic will report the Aptus business as part of its Aortic and Peripheral Vascular division within the Cardiac and Vascular Group. 

Medtronic completed its acquisition of the assets of Aptus Endosystems in a transaction valued at approximately $110 million. Additional terms of the acquisition were not disclosed. The transaction is expected to meet Medtronic's long-term financial metrics for acquisitions, and the annualized earnings impact of this acquisition is not expected to be material, advised the company.

According to Medtronic, Aptus Endosystems’ product portfolio includes the Heli-FX and Heli-FX Thoracic EndoAnchor systems, which feature an endovascularly deployed anchor that is designed to attach a variety of aortic endografts to the native vessel wall. The Heli-FX and Heli-FX Thoracic EndoAnchor systems are cleared by the US Food and Drug Administration for distribution in the United States and have received CE Mark approval for distribution in the European Union.

The Heli-FX and Heli-FX Thoracic EndoAnchor systems can be used with a wide variety of commercially available stent grafts, including Medtronic's Endurant and Valiant stent graft systems.

Medtronic will continue the ANCHOR Registry, which is a global, multicenter, prospective postmarket registry evaluating the Heli-FX aortic securement system. The company also plans to pursue approval for a < 10-mm infrarenal proximal neck indication for Endurant with the use of the Heli-FX EndoAnchor system.

Medtronic noted that the Aptus Heli-FX and Heli-FX Thoracic EndoAnchor systems provide off-the-shelf, customized treatment solutions that minimize the need for complicated procedures for the select subset of patients who would benefit from supplementary fixation. Patients who may benefit from these devices include those with challenging anatomies, risk factors for a secondary intervention, existing seal complications, as well as patients being treated in situations in which a physician may intraoperatively determine the need for additional security.

As part of the acquisition, Medtronic will also distribute, in the United States and Europe, the TourGuide steerable sheath, a device with an adjustable tip that enables quick access and delivery of peripheral vascular products to the most challenging anatomy.

In the company’s press release, Daveen Chopra, Vice President and General Manager of the Aortic Business within the Cardiac and Vascular Group at Medtronic, commented, “We are excited to add this unique complementary, anchor technology to our aortic portfolio. The Heli-FX and Heli-FX Thoracic EndoAnchor systems strongly align with our strategy to invest in treatments that address complex aortic disease with a vision to treat disease of the entire aorta.”

Aptus Endosystems’ President and Chief Executive Officer, James Reinstein, stated, “Medtronic’s acquisition of the Aptus technology is validation of our mission to bring a durable solution to patients with challenging anatomies. Having the Heli-FX available in the broad distribution channels of the market leader, will be very good for our EVAR physicians and their patients.”

Tony Semedo, President, Aortic and Peripheral Vascular within the Cardiac and Vascular Group at Medtronic, added “The aortic business is an important growth engine for Medtronic. We are committed to bringing proven solutions that transform vascular disease management. We believe this acquisition of Aptus will further differentiate Medtronic's offerings in the market.”